Use of PAX8 in endometrial and endocervical adenocarcinomas
Research type
Research Study
Full title
How useful is PAX8 in helping to distinguish between endometrial and endocervical adenocarinomas.
IRAS ID
216172
Contact name
Laurence Seabra
Contact email
Sponsor organisation
Milton Keynes University Hospital
Duration of Study in the UK
0 years, 5 months, 11 days
Research summary
I plan to do a final project for my university course in biomedical science involving the use of the antibody PAX8 with regards to helping differentiate between endocervical and endometrial carcinomas, specifically endocervical adenocarcinoma and endometrioid adenocarcinoma. A similar study has already been done, but the laboratory I’m working at milton keyens university hospital are keen for me to investigate this area as we have recently started using PAX8 but as a replacement for Renal Cell Carcinoma Marker and the pathologists in particular would be interested to know whether it could be useful for helping diagnose the above carcinomas either on its own or as part of a panel. It could potential help in the diagnosis of female genital cancer which can be difficult to diagnose, I plan to hand in my findings to the University of Chester by the 6th April 2017.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
16/NW/0839
Date of REC Opinion
29 Nov 2016
REC opinion
Favourable Opinion